Enhertu 100mg Injection

About

Trastuzumab deruxtecan (Enhertu) is an innovative antibody-drug conjugate (ADC) meticulously engineered to target HER2-expressing cancer cells. It comprises a humanized anti-HER2 monoclonal antibody covalently linked to a potent topoisomerase I inhibitor payload, deruxtecan, via a cleavable tetrapeptide-based linker. This sophisticated design allows for the selective delivery of chemotherapy directly to HER2-positive cancer cells, leading to targeted cellular death while minimizing systemic exposure to the cytotoxic agent. This mechanism significantly reduces off-target toxicity, enhancing the therapeutic index. Enhertu is indicated for the treatment of various advanced HER2-positive malignancies, including unresectable or metastatic HER2-positive breast cancer, HER2-low metastatic breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, and HER2-mutant non-small cell lung cancer, representing a significant advancement in precision oncology.

Uses

• HER2-positive unresectable or metastatic breast cancer.
• HER2-low metastatic breast cancer.
• HER2-positive gastric or gastroesophageal junction adenocarcinoma.
• HER2-mutant non-small cell lung cancer.

Directions For Use

Administered intravenously by a healthcare professional. Dosage and infusion rate are determined by body weight and specific indication.

Benefits

• Targeted delivery of chemotherapy to cancer cells.
• Improved progression-free and overall survival in various HER2-positive cancers.
• Effective in patients previously treated with other HER2-targeted therapies.
• Reduces systemic toxicity compared to conventional chemotherapy.
• Offers a new treatment option for difficult-to-treat cancers.
• Demonstrates durable responses in clinical trials.

Side Effects

• Nausea
• Fatigue
• Alopecia (hair loss)
• Vomiting
• Constipation
• Decreased appetite
• Diarrhea
• Anemia
• Neutropenia
• Thrombocytopenia
• Interstitial Lung Disease (ILD)/Pneumonitis (serious)
• Cardiac dysfunction (rare)

Safety Measures

• Alcohol - No specific interaction, but general advice to limit alcohol during cancer treatment for overall well-being.
• Pregnancy - Contraindicated due to potential for fetal harm. Effective contraception is required during treatment and for 7 months after the last dose.
• Breastfeeding - Not recommended during treatment and for 7 months after the last dose due to potential harm to the breastfed infant.
• Liver - Use with caution in patients with hepatic impairment; close monitoring and potential dose adjustments may be necessary.
• Kidney - Use with caution in patients with renal impairment; no specific dose adjustment guidelines, but monitor renal function.
• Lung - Serious risk of interstitial lung disease (ILD) and pneumonitis. Monitor for new or worsening respiratory symptoms; treatment may need to be interrupted or discontinued.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.